BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma

Journal of Clinical Oncology

Volumn 30, Issue 1, 2012, Pages 34-41

  Kim, Kevin B ^a   Sosman, Jeffrey A ^b   Fruehauf, John P ^c   Linette, Gerald P ^f   Markovic, Svetomir N ^g   McDermott, David F ^h   Weber, Jeffrey S ⁱ   Nguyen, Hoa ^d   Cheverton, Peter ^j   Chen, Daniel ^d   Peterson, Amy C ^d   Carson III, William E ^k   O'Day, Steven J ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

^e SAINT JOHN'S HEALTH CENTER   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; LACTATE DEHYDROGENASE; PACLITAXEL; PLACEBO;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INTESTINE PERFORATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PACLITAXEL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84862908265     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.6270     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006 (Pubitemid 46630937)
3. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000 (Pubitemid 30036349)
4. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22:1118-1125, 2004 (Pubitemid 41095046)
5. Hauschild A, Agarwala SS, Trefzer U, et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830, 2009
6. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
7. Birck A, Kirkin AF, Zeuthen J, et al: Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 9:375-381, 1999 (Pubitemid 29407070)
8. Gorski DH, Leal AD, Goydos JS: Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 197:408-418, 2003 (Pubitemid 38373300)
9. Lacal PM, Failla CM, Pagani E, et al: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115:1000-1007, 2000 (Pubitemid 32037443)
10. Marcoval J, Moreno A, Graells J, et al: Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24:212-218, 1997 (Pubitemid 27187016)
11. Ugurel S, Rappl G, Tilgen W, et al: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577-583, 2001 (Pubitemid 32112873)
12. Nagengast WB, Lub-de Hooge MN, Hospers GA, et al: Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008
13. Salven P, Heikkila P, Joensuu H: Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 76:930-934, 1997 (Pubitemid 27401946)
14. Simonetti O, Lucarini G, Brancorsini D, et al: Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95:1963-1970, 2002 (Pubitemid 35222177)
15. Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159:223-235, 2001 (Pubitemid 33704207)
16. Vlaykova T, Laurila P, Muhonen T, et al: Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 9:59-68, 1999 (Pubitemid 29169990)
17. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
18. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
19. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
20. Rao RD, Holtan SG, Ingle JN, et al: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106:375-382, 2006 (Pubitemid 43100447)
21. Perez DG, Suman VJ, Fitch TR, et al: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N047A. Cancer 115:119-127, 2009
22. Zimpfer-Rechner C, Hofmann U, Figl R, et al: Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13:531-536, 2003 (Pubitemid 37266956)
23. Markman M, Kennedy A, Webster K, et al: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141, 1999
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Bedikian AY, Johnson MM, Warneke CL, et al: Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26:624-633, 2008 (Pubitemid 351918588)
26. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008 (Pubitemid 351264344)
27. Hersey P, Bastholt L, Chiarion-Sileni V, et al: Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 20:vi35-vi40, 2009 (suppl 6)
28. Koukourakis MI, Giatromanolaki A, Winter S, et al: Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology 77:285-292, 2009
29. Koukourakis MI, Kontomanolis E, Giatromanolaki A, et al: Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. Gynecol Obstet Invest 67:162-168, 2009
30. Varker KA, Biber JE, Kefauver C, et al: A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14:2367-2376, 2007 (Pubitemid 47174913)
31. Combination of temozolomide and sunitinib in treatment of patients with metastatic and unresectable malignant melanoma. http://www.clinicaltrials.gov/ ct2/show/NCT00859326
32. Clinical trial of sutent to treat metastatic melanoma. http://www.clinicaltrials.gov/ct2/show/NCT00631618
33. Trial of single agent sunitinib for patients with chemo-refractory metastatic melanoma. http://www.clinicaltrials.gov/ct2/show/NCT01216657
34. Temozolomide and sunitinib malate in treating patients with stage III or stage IV malignant melanoma. http://www.clinicaltrials.gov/ct2/show/NCT01005472
35. A phase I/Ib, multicenter, open-label, dose escalation study of E7080 in patients with solid tumors and in combination with temozolomide in patients with advanced and/or metastatic melanoma. http://www.clinicaltrials.gov/ct2/show/ NCT00121680
36. An open-label, 2-cohort, multicenter, study of E7080 in previously treated subjects with unresectable stage III or stage IV melanoma. http://www.clinicaltrials.gov/ct2/show/NCT01136967
37. E7080 in combination with dacarbazine versus dacarbazine alone as first line therapy in patients with stage IV melanoma. http://www.clinicaltrials.gov/ ct2/show/NCT01133977
38. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
39. Kumar R, Angelini S, Hemminki K: Activating BRAF and N-Ras mutations in sporadic primary melanomas: An inverse association with allelic loss on chromosome 9. Oncogene 22:9217-9224, 2003 (Pubitemid 38122033)
40. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
41. Sosman J, Kim K, Schuchter L: An open-label, multicenter phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Presented at the Society for Melanoma Research 7th International Melanoma Research Congress, Sydney, New South Wales, Australia, November 4-7, 2010